ALNY

Alnylam Pharmaceuticals, Inc.

PHARMACEUTICAL PREPARATIONS

Congressional Trades

by 2 members

Ticker disclosure brief

Congressional disclosure records for ALNY

A ticker-first view of recent disclosures, reported ranges, filing lags, party aggregates, federal awards, lobbying records, and source-linked receipts.

Latest receipt

Jefferson Shreve

SELL · 2025-05-12

Largest range

$15K – $50K

Jefferson Shreve

Longest observed gap

42d

Jefferson Shreve

Highest 30d vs SPY

26.8%

Josh Gottheimer

Purchase rows

Sale rows

100%

Disclosed midpoint

$114K

range estimate

Unique Traders

members

Disclosure timing method

Observed filing gaps are not notice-date findings

The reporting deadline is the earlier of 30 days after notice or 45 days after the transaction. Public disclosure rows provide transaction and filing dates, but do not establish when a member received notice. PoliWealth therefore marks only transaction-to-filing gaps over 45 days as an apparent delay for review; 31–45 day gaps are not labeled late from transaction date alone.

Open >45-day tracker Official rule ↗

Party Breakdown

Democrats2 · 40%

Republicans3 · 60%

Lobbying filings

all →

2026-07-05$50K
ALNYLAM PHARMACEUTICALS INC.
General Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862: ORPHAN Cures Act. Pediatric Review Reauthorization.
2026-04-20$430K
ALNYLAM PHARMACEUTICALS INC.
Issues related to the implementation of the Inflation Reduction Act; HR.4993, Joe Fiandra Access to Home Infusion Act; issues related to MFN drig pricing Issues relating to supply chain tariffs Implementation of The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (PL 116-94); issues related to drug pricing; FY2026 Labor HHS appropriations, issues related to genetically targeted technologies; HR1672, Maintaining Investments in New Innovation Act.
2026-04-20$60K
ALNYLAM PHARMACEUTICALS INC.
RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; H.R. 1672, Maintaining Investments in New Innovation Act; P.L. 119-21; U.S. Competitiveness
2026-04-20$60K
ALNYLAM PHARMACEUTICALS INC.
Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation Act. H.R.946: ORPHAN Cures Act.
2026-04-17$60K
ALNYLAM PHARMACEUTICALS INC.
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
2026-04-17$50K
ALNYLAM PHARMACEUTICALS INC.
General Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862: ORPHAN Cures Act. Pediatric Review Reauthorization.
2026-04-16$60K
ALNYLAM PHARMACEUTICALS INC.
Issues regarding FDA guidance on Platform Technology Platform Technology Designation Program for Drug Development.
2026-01-20$390K
ALNYLAM PHARMACEUTICALS INC.
Implementation of The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (PL 116-94); issues related to drug pricing. Issues related to the implementation of the Inflation Reduction Act; HR.4993, Joe Fiandra Access to Home Infusion Act Issues relating to supply chain tariffs
2026-01-20$60K
ALNYLAM PHARMACEUTICALS INC.
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
2026-01-20$60K
ALNYLAM PHARMACEUTICALS INC.
RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; H.R. 1672, Maintaining Investments in New Innovation Act; H.R. 946/S. 1862, ORPHAN Cures Act; P.L. 119-21; U.S. Competitiveness

Loading trade analytics…

All Disclosed Trades

Page 1 · 5 of 5 shown

Date	Member	Action	Amount	Observed Gap	Receipt
2025-05-12	RJefferson Shreve	SELL	$15K – $50K	42d	receipt →
2025-05-12	RJefferson Shreve	SELL	$15K – $50K	41d	receipt →
2025-05-12	RJefferson Shreve	SELL	$15K – $50K	3d	receipt →
2024-01-29	DJosh Gottheimer	SELL	$1K – $15K	17d	receipt →
2024-01-29	DJosh Gottheimer	SELL	$1K – $15K	17d	receipt →

“Observed gap” is the calendar distance from transaction date to filing date; only gaps over 45 days receive an apparent-delay marker.